Gambaran Umum
BioInvent International AB, based in Sweden, operates within the biotechnology sector, focusing on the research and development of novel immuno-modulatory antibodies for the treatment of cancer. Leveraging its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library, BioInvent is adept at identifying novel targets and producing therapeutic antibodies that enhance the immune response against cancer cells. Key projects include the development of BI-1206, its flagship antibody therapy chiefly targeting non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The company's strategic collaborations extend its research capabilities and market reach, notably enhancing its project pipeline with several early to mid-stage clinical trials in oncology, underscoring its commitment to innovative cancer therapies.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk BioInvent International AB (publ) per 2025 Jun 30 adalah 254.29 MM.
- Nilai operating income untuk BioInvent International AB (publ) per 2025 Jun 30 adalah -321.87 MM.
- Nilai net income untuk BioInvent International AB (publ) per 2025 Jun 30 adalah -291.95 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 254.29 | -321.87 | -291.95 |
2025-03-31 | 60.80 | -504.32 | -468.06 |
2024-12-31 | 44.69 | -471.25 | -429.38 |
2024-09-30 | 38.64 | -456.73 | -409.65 |
2024-06-30 | 52.67 | -430.90 | -383.48 |
2024-03-31 | 61.15 | -379.33 | -334.52 |
2023-12-31 | 71.46 | -370.56 | -330.30 |
2023-09-30 | 76.78 | -337.83 | -311.48 |
2023-06-30 | 67.91 | -325.66 | -304.28 |
2023-03-31 | 325.72 | -63.13 | -48.49 |
2022-12-31 | 326.13 | -50.47 | -42.50 |
2022-09-30 | 310.39 | -50.32 | -42.93 |
2022-06-30 | 295.46 | -43.60 | -41.66 |
2022-03-31 | 29.84 | -266.49 | -266.40 |
2021-12-31 | 19.38 | -278.17 | -278.44 |
2021-09-30 | 113.22 | -169.58 | -171.16 |
2021-06-30 | 126.50 | -139.96 | -141.44 |
2021-03-31 | 136.86 | -121.95 | -123.48 |
2020-12-31 | 147.37 | -74.96 | -76.33 |
2020-09-30 | 74.02 | -144.49 | -145.79 |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -6.22 | -6.22 |
2024-06-30 | -5.82 | -5.82 |
2024-03-31 | -5.08 | -5.08 |
2023-12-31 | -5.02 | -5.02 |
2023-09-30 | -4.78 | -4.77 |
2023-06-30 | -4.67 | -4.67 |
2023-03-31 | -0.77 | -0.76 |
2022-12-31 | -0.69 | -0.69 |
2022-09-30 | -0.71 | -0.71 |
2022-06-30 | -0.71 | -0.71 |
2022-03-31 | -4.56 | -4.55 |
2021-12-31 | -5.14 | -5.14 |
2021-09-30 | -3.52 | -3.53 |
2021-06-30 | -3.26 | -3.26 |
2021-03-31 | -3.63 | -3.63 |
2020-12-31 | -2.66 | -2.66 |
2020-09-30 | -5.96 | -5.95 |
2020-06-30 | -7.37 | -7.37 |
2020-03-31 | -7.29 | -7.29 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk BioInvent International AB (publ) per 2025 Jun 30 adalah -248.58 MM.
- Nilai cash from investing activities untuk BioInvent International AB (publ) per 2025 Jun 30 adalah 206.37 MM.
- Nilai kas dari aktivitas pendanaan untuk BioInvent International AB (publ) per 2025 Jun 30 adalah -8.79 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -248.58 | 206.37 | -8.79 |
2025-03-31 | -434.57 | 449.97 | -8.62 |
2024-12-31 | -380.47 | 564.35 | -8.46 |
2024-09-30 | -354.55 | 482.00 | -8.28 |
2024-06-30 | -363.74 | 256.87 | -8.12 |
2024-03-31 | -328.67 | 254.74 | -7.97 |
2023-12-31 | -341.69 | 59.68 | 23.14 |
2023-09-30 | -340.97 | 204.42 | 23.62 |
2023-06-30 | -61.95 | -265.36 | 303.80 |
2023-03-31 | -40.35 | -494.09 | 304.12 |
2022-12-31 | -41.23 | -628.85 | 273.49 |
2022-09-30 | -45.30 | -788.39 | 273.48 |
2022-06-30 | -275.56 | -636.74 | -6.13 |
2022-03-31 | -276.12 | -525.12 | -6.04 |
2021-12-31 | -245.84 | -467.54 | 894.87 |
2021-09-30 | -140.91 | -200.71 | 956.03 |
2021-06-30 | -114.77 | -8.13 | 1,450.27 |
2021-03-31 | -77.75 | -7.68 | 1,545.39 |
2020-12-31 | -62.62 | -6.70 | 644.62 |
2020-09-30 | -118.98 | -6.42 | 583.60 |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -4.84.
- p/libro untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah 2.95.
- p/tbv untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah 2.95.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -4.84 | 2.95 | 2.95 |
2025-03-31 | -4.51 | 2.19 | 2.19 |
2024-12-31 | -6.25 | 2.55 | 2.55 |
2024-09-30 | -6.98 | 2.44 | 2.44 |
2024-06-30 | -7.51 | 2.04 | 2.04 |
2024-03-31 | -7.59 | 1.91 | 1.91 |
2023-12-31 | -8.05 | 1.78 | 1.78 |
2023-09-30 | -8.24 | 1.70 | 1.70 |
2023-06-30 | -7.07 | 1.46 | 1.46 |
2023-03-31 | -44.38 | 1.38 | 1.38 |
2022-12-31 | -57.66 | 1.47 | 1.47 |
2022-09-30 | -49.49 | 1.26 | 1.26 |
2022-06-30 | -45.89 | 1.30 | 1.30 |
2022-03-31 | -7.18 | 1.47 | 1.47 |
2021-12-31 | -13.02 | 1.54 | 1.54 |
2021-09-30 | -11.17 | 1.32 | 1.32 |
2021-06-30 | -13.52 | 1.27 | 1.27 |
2021-03-31 | -15.48 | 1.22 | 1.22 |
2020-12-31 | -9.98 | 2.23 | 2.23 |
2020-09-30 | -8.57 | 1.91 | 1.91 |
2020-06-30 | -5.09 | 3.95 | 3.95 |
2020-03-31 | -4.57 | 4.81 | 4.81 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.26.
- EBIT (3 tahun) / EV untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.21.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.26 | -0.21 |
2025-03-31 | -0.29 | -0.18 |
2024-12-31 | -0.22 | -0.14 |
2024-09-30 | -0.17 | -0.11 |
2024-06-30 | -0.16 | -0.11 |
2024-03-31 | -0.15 | -0.10 |
2023-12-31 | -0.16 | -0.09 |
2023-09-30 | -0.16 | -0.08 |
2023-06-30 | -0.19 | -0.10 |
2023-03-31 | -0.03 | -0.09 |
2022-12-31 | -0.02 | -0.07 |
2022-09-30 | -0.03 | -0.08 |
2022-06-30 | -0.03 | -0.08 |
2022-03-31 | -0.23 | -0.16 |
2021-12-31 | -0.18 | -0.15 |
2021-09-30 | -0.26 | -0.23 |
2021-06-30 | -0.35 | -0.34 |
2021-03-31 | -0.37 | -0.39 |
2020-12-31 | -0.18 | -0.16 |
2020-09-30 | -0.24 | -0.22 |
2020-06-30 | -0.26 | -0.22 |
2020-03-31 | -0.27 | -0.23 |
Efektivitas Manajemen
- roa untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.39.
- roe untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.43.
- roic untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.60.
- croic untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah 0.01.
- ocroic untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -0.55.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.39 | -0.43 | -0.60 | 0.01 | -0.55 |
2025-03-31 | -0.32 | -0.35 | -0.48 | 0.19 | -0.42 |
2024-12-31 | -0.28 | -0.29 | -0.40 | 0.13 | -0.35 |
2024-09-30 | -0.28 | -0.29 | -0.34 | -0.09 | -0.33 |
2024-06-30 | -0.20 | -0.21 | -0.27 | -0.06 | -0.26 |
2024-03-31 | -0.19 | -0.21 | -0.25 | -0.19 | -0.26 |
2023-12-31 | -0.18 | -0.18 | -0.22 | -0.07 | -0.24 |
2023-09-30 | -0.20 | -0.21 | -0.20 | -0.01 | -0.04 |
2023-06-30 | -0.03 | -0.21 | -0.20 | -0.01 | -0.04 |
2023-03-31 | -0.03 | -0.04 | -0.03 | -0.14 | -0.03 |
2022-12-31 | -0.03 | -0.03 | -0.03 | -0.33 | -0.03 |
2022-09-30 | -0.03 | -0.03 | -0.03 | -0.33 | -0.03 |
2022-06-30 | -0.17 | -0.03 | -0.03 | -0.62 | -0.18 |
2022-03-31 | -0.17 | -0.17 | -0.20 | -0.61 | -0.21 |
2021-12-31 | -0.24 | -0.26 | -0.12 | 0.42 | -0.10 |
2021-09-30 | -0.24 | -0.26 | -0.12 | 0.42 | -0.07 |
2021-06-30 | -0.56 | -0.73 | -0.09 | 0.86 | -0.07 |
2021-03-31 | -0.64 | -0.90 | -0.08 | 0.93 | -0.05 |
2020-12-31 | -0.53 | -0.69 | -0.22 | 0.69 | -0.18 |
2020-09-30 | -0.53 | -0.69 | -0.22 | 0.69 | -0.18 |
2020-06-30 | -0.47 | -0.61 | -0.73 | -0.14 | -0.54 |
2020-03-31 | -1.02 | -1.60 | -0.95 | 0.59 | -0.80 |
Gross Margins
- marjin kotor untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah 1.00.
- marjin bersih untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -7.70.
- marjin operasi untuk BioInvent International AB (publ) pada 2025 Jun 30 adalah -8.29.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 1.00 | -7.70 | -8.29 |
2025-03-31 | 1.00 | -9.61 | -10.54 |
2024-12-31 | 1.00 | -10.60 | -11.82 |
2024-09-30 | 1.00 | -7.28 | -8.18 |
2024-06-30 | 1.00 | -5.47 | -6.20 |
2024-03-31 | 1.00 | -4.62 | -5.18 |
2023-12-31 | 1.00 | -4.06 | -4.40 |
2023-09-30 | 1.00 | -4.48 | -4.80 |
2023-06-30 | 1.00 | -4.48 | -4.80 |
2023-03-31 | 1.00 | -0.15 | -0.19 |
2022-12-31 | 1.00 | -0.14 | -0.16 |
2022-09-30 | 1.00 | -0.14 | -0.16 |
2022-06-30 | 1.00 | -0.14 | -0.15 |
2022-03-31 | 1.00 | -8.93 | -8.93 |
2021-12-31 | 1.00 | -1.51 | -1.50 |
2021-09-30 | 1.00 | -1.51 | -1.50 |
2021-06-30 | 1.00 | -1.12 | -1.11 |
2021-03-31 | 1.00 | -0.90 | -0.89 |
2020-12-31 | 1.00 | -1.97 | -1.95 |
2020-09-30 | 1.00 | -1.97 | -1.95 |
2020-06-30 | 1.00 | -1.98 | -1.96 |
2020-03-31 | 1.00 | -1.54 | -1.53 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) |